Fentanyl is a potent, short-acting narcotic analgesic widely used as a surgical anesthetic and for the control of pain when administered in the form of a transdermal patch. The success of the patch can be attributed to fentanyl's low molecular weight and its highly lipophilic nature, which enables it to be readily absorbed through the skin and subsequently distributed throughout the body. Over the past three years, the Los Angeles County Coroner's Toxicology Laboratory has encountered 25 cases involving Duragesic patches (fentanyl), and their postmortem tissue distributions are presented here. The analysis of fentanyl from postmortem specimens (3-mL or g sample size) consisted of an n-butyl chloride basic extraction followed by identification and quantitation on a gas chromatograph-mass spectrometer using the selected ion monitoring (SIM) mode. The fentanyl ions monitored were m/z 245, 146, and 189 and the internal standard, fentanyl-d~ ions, were m/z 250, 151, and 194 (quantitation ion underlined). The linear range of the assay was 1.67 pg/L to 500 pg/L with the limit of quantitation and detection of 1.67 ug/L. The postmortem tissue distribution ranges of fentanyl in the 25 fatalities were as follows: heart blood, 1.8-139 pg/L (23 cases); femoral blood, 3.1--43 pg/L (13 cases); vitreous, +<2.0-20 pg/L (4 cases); liver, 5.8-613 pg/kg (22 cases); bile, 3.5-262 pg/L (15 cases); urine, 2.9-895 pg/L (19 cases); gastric, 0-1200 pg total (17 cases); spleen, 7.0-79 pg/kg (3 cases); kidney, 11 pg/kg (1 case); and lung, 31 pg/kg (1 case). The age of the decedents in this study ranged from 19 to 84, with an average age of 46. The modes of death included 15 accidental, 5 natural, 3 suicidal, and 2 undetermined. The main objectives of this paper are to show the prevalence of fentanyl patches in our community and to aid the forensic toxicologist with the interpretation of postmortem fentanyl levels in casework.
Introduction
The Duragesic patch (fentanyl, N-phenyl-N-(1-2-phenylethyl-4-piperidyl) propanamide) is a high-potency, short-acting drug manufactured by Janssen Pharmaceutica, Inc. for the manage-* Author to whom correspondence should be addressed. ment of chronic pain. Fentanyl is a schedule II, synthetic phenylpiperdine derivative closely related to meperidine (1, 2) . On a weight-for-weight basis, fentanyl is 50 to 100 times more potent than morphine and should be considered to have a potential for abuse (3) . Fentanyl has a molecular formula of C22H2sN20 ( Figure 1 ), a molecular weight of 336.5 (1) , and lipophilic properties allowing it to be readily absorbed (46-66% of a given dose) through the skin (2) . However, the degree of absorption depends on where the patch is applied. Pharmacologically, fentanyl acts on the central nervous system causing analgesia, sedation, severe respiratory depression, muscle rigidity, seizures, coma, and hypotension (4) . Adverse reactions include mood changes, euphoria, dysphoria, drowsiness, constricted pupils, nausea, and vomiting (5) . In general, fentanyl increases the patients' tolerance to pain and decreases the perception of suffering. Reproduction (photocopying) of editorial content of this journal is prohibited without publisher's permission. Decedent was found unresponsive inside a residence where he was Pulmonary edema and congestion of the partying with others, drinking alcohol, and using what they called lungs. Frothy foam noted in the airways. "morphine patches". The decedent's father, who recently died of cancer, had been prescribed fentanyl patches for pain. The decedent had a history of drug abuse, and a friend admitted removing a "morphine patch" from the body prior to paramedic-police intervention.
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The decedent was involved in a domestic dispute and barricaded himself inside his residence when the police were called. He had a long history of drug abuse and had recently undergone back surgery. He was subsequently found by the police unresponsive with a hypodermic needle laying at his side.
Decedent was diagnosed with AIDS and had respiratory problems. He also had a history of drug abuse.
Decedent was known to use methamphetamine and was diagnosed with terminal AIDS, pneumonia, and cancer. He was found unresponsive at his residence.
Decedent had a history of pleural mesothelioma due to asbestos exposure. He was under hospice care where he was being treated with morphine and fentanyl patches.
Decedent had been diagnosed with AIDS, substance abuse, and was suicidal. He was found unresponsive by his roommate who informed police officers that the decedent had just purchased "morphine" patches and had worn 6 patches the morning prior to his death. Decedent was found unresponsive at his residence. He suffered from hypertension and asbestos exposure.
Decedent suffered from chronic pain due to her severe back problems caused by three separate car accidents. She was prescribed Duragesic patches for the first time which caused the decedent discomfort and itching throughout her body. Decedent was found unresponsive in bed during a welfare check.
Decedent had a history of cocaine and alcohol abuse. He was found unresponsive in his apartment during a welfare check. A package of Duragesic patches, and bottles of valproic acid and sertraline were found on the bathroom counter. Decedent was exposed to asbestos. He was under hospice care and was pronounced dead at his residence. Decedent had a history of heavy smoking and forging prescription medication orders. She was found unresponsive on the floor of her residence.
Decedent was diagnosed with sarcomatous mesothelioma of the right lung. Decedent complained of constant pain and remained in hospital until his death.
Decedent was diagnosed with mesothelioma (intestinal) as a result of an asbestos exposure at work. He was taking multiple pain medications and using "pain patches". Decedent died at home. Medications included hydromorphone and fentanyl patches (25 pg/h and 100 pg/h).
Decedent complained of lower back pain for a few weeks prior to his death and was prescribed tramadol. He was found unresponsive in his bedroom.
Decedent had a 25-year history of chronic back pain due to a degenerative disk disease. He had a history of drug abuse and had access to the following medications: clonazepam, venlafaxine, hydrocodone, buspirone, dextromethorphan, and fentanyl patches. The decedent was found unresponsive in his bedroom.
Decedent suffered from diabetes, urosepsis, and several other medical problems. The decedent received hospice care at home.
Decedent had many medical problems including blindness, osteoporosis, arthritis, and refused to eat. She was found unresponsive in a retirement home. A fentanyl patch (25 IJg/h) was applied the day prior to her death.
Decedent had clinical depression, attempted suicide several times with medications, and had a history of psychiatric hospitalizations. She was found unresponsive in a retirement home with an empty nortriptyline vial and a suicide note by her side.
Acute and chronic myocardial infarct and severe coronary atherosclerosis. Six patches (100 pg/h)were recovered, 2 from the shoulders, and 4 from the lower back.
Acute arteriosclerotic cardiovascular disease, 40% narrowing of the left coronary artery and visceral congestion.
Unremarkable other than a patch removed from abdomen area during autopsy.
Morbid obesity, fatty liver, and a fentanyl patch recovered from the mid-lumbar spine.
Early stages of decomposition. Cardiomegaly (500 g) with occlusive atherosclerosis of the coronaries, tn addition, moderate pulmonary congestion and edema. Two patches (50 & 100 pg/h) were recovered from the left arm.
Large left renal multilocolated abscess with extension into the abdomen. Hepatomegaly-acute passive congestion, slenomegaly-acute passive congestion and moderate pulmonary edema/congestion. Two patches were recovered from the left and right upper anterior chest region.
Bronchopneumonia, severe pulmonary and aortic thrombosis.
Many undigested tablets remained in the gastric contents. A fentanyl patch (50 pg/h) was recovered from the right shoulder, and an unmarked patch was recovered from the lower left abdomen area of the decedent. Decedent was diagnosed with Werners Disease, advanced osteoporosis, and early stages of senile dementia. She had attempted suicide twice by overdose. Decedent was found unresponsive at her residence by her boyfriend. She was sent to a mortuary and embalmed; however, her attending physician would not sign the death certificate.
Decedent was diagnosed with spine cancer and was prescribed fentanyl patches. He periodically received radiation therapy at a hospital and one day was found unresponsive on the roof of that building.
Decedent had liver cancer and received hospice care. Suspicious circumstances surrounded this death because the caretakers represented themselves as the family where they attempted to have the deceased cremated. The decendent's will had been changed to include the new caretakers. Medication included a fentanyl patch (25 pg/h).
Embalmed body, history of Werners Disease, hypertension, chronic obstructive pulmonary disease, and generalized artherosclerosis. A fentanyl patch (75 pg/h) was recovered from the right side, above the breast.
Visceral congestion, squamous cell carcinoma of the lung with necrosis and evidence of radiation effect. In addition, metastatic tumor to the liver.
Atherosclerotic coronary heart disease and sixty percent narrowing of the right coronary artery.
The Duragesic patch ( Figure 2) consists of four layers. The outermost layer is made of a polyester film. The drug reservoir contains the fentanyl and an alcohol gel with hydroxyethyl cellulose, which enhances the drug delivery rate through the copolymer ultimately increasing the permeability of the skin. The release membrane consists of an ethylene vinyl acetate copolymer membrane, which controls the rate of fentanyl delivery. The last layer, closest to the skin, is the adhesive material, which is a fentanyl-containing silicone adhesive material (1, 3) . The patch is prescribed in four delivery doses per 72 h: 25, 50, 75, and 100 lJg/h with 2.5, 5.0, 7.5, and 10 mg of fentanyl, respectively (4). Contraindications of the patch include management of acute or postoperative pain, management of mild pain responsive to nonopioid therapy, and children under the age of 12 or patients under the weight of 50 kg. Initial therapy is not to exceed a dose of 25 tJg/h, and for opioid-tolerant patients, doses prescribed can be 50, 75, and 100 ~g/h (1, 5) .
Fentanyl is rapidly absorbed into the skin, forming a depot of drug in the upper layers of the skin (1). It is absorbed by the lungs and fat tissue, then slowly released into the systemic circulatory system. Serum concentrations are undetectable for 2 h, then rise gradually for 12-14 h reaching steady state at 24 h. Steady-state plasma level ranges attained for the 25, 50, 75, and 100 IJg/h dose patches are 0.30-1.2 lJg/L, 0.60-1.8 IJg/L, 1.1-2.6 IJg/L, and 1.9-3.8 lJg/L, respectively (4). Absorption also continues up to 12 h after the removal of the patch. Respiratory depression occurs at a fentanyl concentration range of 1-5 IJg/L, loss of consciousness occurs at 34 • 7 ug/L and the minimum effective concentration to produce an analgesic effect is 0.63 • 0.25 ug/L. Fentanyl is highly lipophilic and has a volume of distribution of 3 • 8 L/kg (2). It is metabolized in the liver being transformed by N-dealkylation to norfentanyl; 50% is eliminated in the urine within the first 8 h, and 85% of the drug is recovered in the urine within 72 h (2,4).
Case Histories
Over a period of three years, the Los Angeles County Coroner has encountered 25 fatalities where the decedent was administered fentanyl through a transdermal patch system. In Table I , the gender, age, height, weight, and circumstances of the case along with the pathologist's autopsy findings are presented.
Experimental Specimens
All specimens were collected at the time of autopsy. Time interval between notification of death and collection varied from 24 to 72 h. Heart blood samples were collected and preserved with sodium fluoride. Peripheral blood samples from the femoral vein were collected and preserved with sodium fluoride and potassium oxalate. All other autopsy specimens such as vit-reous, liver, bile, urine, gastric contents, spleen, kidney, and lung tissue were stored without preservative. All biological specimens were stored at 4~
Materials
Fentanyl and fentanyl-ds, both of a citrate salt, were purchased from Sigma Chemical Co. and prepared as 1.0 g/L stock solutions in methanol. All reagents were analytical grade and purchased from various vendors.
Extraction
Seventy-five microliters 75 IJL of internal standard, (fentanyl-ds, 1 rag/L), 3 mL buffer (20% sodium carbonate), and 6 mL of n-butyl chloride were added to 3 mL of standard, blood sample, or tissue homogenate. After rotation for 20 min and centrifugation, the organic layer was separated and transferred to a test tube. Two milliliters of 0.10N hydrochloric acid was added to the organic layer, and the sample was vortex mixed for 20 s. Following centrifugation and aspiration of the organic layer to waste, the aqueous layer was washed with 4 mL 2-methylbutane by vortex mixing for 15 s. The organic layer was aspirated to waste. The aqueous layer was made alkaline with 1 mL 20% sodium carbonate buffer and extracted with 4 mL 2-methylbutane by vortex mixing for 20 s. The organic layer was evaporated to dryness, the residue reconstituted with 50 IlL methanol, and subsequently transferred to autosampler vials for instrumentation.
Instrumentation
A Hewlett-Packard model 5890 gas chromatograph (GC) equipped with a 5970 mass selective detector (MSD) and 7673 autosampler was used for identification and quantitation of fentanyl. The MSD was operated in the selected ion-monitoring mode (SIM). The fentanyl ions monitored were m/z 245, 146, and 189 and the internal standard, fentanyl-ds, ions were m/z 250, 151, and 194 (quantitation ion underlined). The GC was equipped with a HP-5 (15 m x 0.25-mm i.d., 0.25-1Jm film thickness) capillary column, the carrier gas (helium) was set at a flow rate of 3.0 mL/min, and the oven temperature was programmed at 10~ from 200~ to 280~ with a final hold for I min (total analysis time of 9 rain). The injection and detection port temperatures were 280~ and 300~ respectively.
Results
Specimens from the 25 cases were submitted for toxicological analysis. Heart blood samples were tested for volatiles by headspace GC, screened for drugs of abuse (cocaine, opiates, methamphetamine, phencyclidine, and barbiturates) by radioimmunoassay, and screened for therapeutic drugs (bases) by GC-nitrogen-phosphorus detection. The L.A. County Coroner's laboratory does not use an immunoassay to screen for fentanyl. Fentanyl must be specifically recognized in the case history, or may be detected in our therapeutic drug screen. Quantitation of fentanyl was achieved by the comparison of known standard quantities to extracted specimens by GC-MS. The assay was linear from 1.67 to 500 pg/L, with the limit of quantitation and detection established at 1.67 pg/L. Postmortem concentrations of fentanyl, other drugs detected, and cause and manner of death for each of the 25 cases are detailed in Table II . For discussion purposes, the 25 cases were organized by mode of death: 15 accidental, 5 natural, 3 suicidal, and 2 undetermined. The cause and mode of death in these case studies were determined by the medical examiner after careful consideration of all available information.
Discussion
Of the 25 cases evaluated, 8 cases (5, 8, 15, 17, 19, 20, 24 , and 25) were clearly not fentanyl related. Their postmortem heart blood levels averaged 3.6 ~g/L (range < 2-7 lJg/L), with no apparent redistribution at these concentrations observed in the three cases where both the heart blood and femoral blood levels were measured. The fentanyl liver levels in these same eight cases averaged 14.6 pg/kg (range 5.8-31 pg/kg).
Twelve of the 25 cases were drug-related deaths with three cases (1, 2, and 9) attributed solely to fentanyl. Seven of the remaining nine multiple drug deaths had significant heart blood fentanyl levels, averaging 50 pg/L (range 16-139 pg/L), and in five of these seven cases, fentanyl appeared to be the immediate cause of death. The liver levels in these cases ranged from 69 to 352 pg/kg with an average of 167 ~g/kg. In case 21, we believed it was the nortriptyline that was the cause of death and the fentanyl blood level (6.3 pg/L) and liver (14 pg/kg) represented therapeutic use. Case 23 was embalmed, and no blood level was available.
The remaining five cases were of particular interest. Two of the cases (11 and 16) had high fentanyl levels, 22 ~g/L and 47 IJg/L, respectively, in the heart blood and 19 l~g/L and 24 ~g/L, respectively, in the femoral blood. Both of these decedents were cancer patients presumably on chronic fentanyl therapy, and the high fentanyl levels may represent tolerance to the drug. Two cases appeared to be misdiagnosed. Case 18 had a blood fentanyl level of 81 pg/L and a liver level of 613 IJg/kg and appeared to be a clear fentanyl overdose that was reported to be a natural death. Case 12 had a blood fentanyl concentration of 6.4 pg/L and liver level of 47 pg/kg and was reported as an acute fentanyl overdose, but in light of this study, may actually represent therapeutic use. The last case (10) had unusual results. The fentanyl heart blood level measured 3.5 IJg/kg which appeared to be consistent with therapeutic use, but the liver level was 78 pg/kg, consistent with other overdose cases in this study. Because the decedent was found in early stages of decomposition, we questioned the source and validity of the blood sample, especially because the fentanyl liver level supported the cause of death as fentanyl use.
The number of Duragesic patches recovered in these cases varied. In 10 cases a single Duragesic patch was recovered; in 6 cases 2 patches were recovered; 1 decedent had 6 patches; and still another decedent had 11 patches. However, without accurate dosage and administration information for these cases, no correlation should be attempted between the number of patches recovered and the fentanyl blood concentrations measured.
A review of the literature produced just one other case of a fentanyl overdose (6) . This was a case of an 83-year-old female who was found unresponsive with three 100 pg/h patches on her chest. Her measured blood fentanyl concentration was 25 pg/L, and the liver level was 104 pg/kg. Both were consistent with overdose levels reported in this study.
